Furthermore, studies conducted by Ni et al. [118] and Hu et al. [119] identified a high pre-treatment serum PLT–ALB–BIL grade as an independent predictor for worse OS in HCC patients receiving TACE combined with PMWA or molecular targeted therapy with sorafenib. This evidence concerns the gene ALB and hepatocellular carcinoma.